EGFR and non-small cell lung carcinoma: This multi-cohort, prospective, phase 2 clinical trial aimed to investigate the efficacy and safety of SMET12 plus toripalimab and chemotherapy among advanced NSCLC patients tested positive for EGFR protein that were treatment-naïve, with resistance to first-line immune checkpoint inhibitors-containing therapy and harbor EGFR mutations and acquire resistance to first-line EGFR-TKIs, and to evaluate the associations of lymphocyte numbers and differentiation pattern with therapeutic efficacy among advanced NSCLC patients through detection of peripheral blood lymphocytes with flow cytometry.